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Abstract: Three decades of work in the feminist studies of science and 
technology have shaped our evolving understandings of the relationships 
between sex, gender, and biotechnology. Sex, and gender are most often 
reduced to binary categories, severely limiting our conceptions not only of 
human diversity, but those of science and technology. Using two case study 
set in India, transnational surrogacy and the Indian Genome Variation Project, 
this paper explores how popular positions around biotechnology are reduced 
to binary positions promoting and opposing biotechnology as the solution for 
the economic and social development of India. By locating surrogacy and 
genomics within the larger geopolitical, historical, economic and cultural 
transformations of postcolonial India, the paper argues that both technologies 
are far more complex in their impact on women and gender. Why does 
technology become the major site of hope for the future? Why does genomics 
become the site for the promises of good health? Why has India become a site 
for reproductive tourism, and transnational surrogacy in particular? Drawing 
on the social studies of science, the paper argues that technology and human 
bodies are never neutral but always prefigured with a gender, race, caste and 
sexuality. Surrogacy and genomics should be understood within these colonial 
and postcolonial histories of science and technology.
 Keywords: Transnational Surrogacy, Genomics, Feminism, Gender, Women
Introduction
In her famous essay, “Why it is difficult for us to count past two,” Evelyn 
Fox Keller  (1992) describes how when asked about her work, she tells 
people that she researches issues of gender and the sciences, yet, she 
is continually asked to discuss what she had learned about women in 
the sciences. Despite decades of feminist explication of the differences 
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between sex and gender, she argues, most people constantly conflate the 
two. She laments about our incapacity to count past two. Two decades later, 
the binaries endure. The “binary” world we live in can be striking: we talk 
about men and women, masculine and feminine, upper class and lower class, 
upper caste and lower caste, black and white, homosexual and heterosexual, 
trans and cis, ability and disability, etc. In reality, none of these categories is 
binary, but rather represent a range of people in multiple categories if not a 
continuum. Yet the impulse to categorise this diversity into two categories, 
one superior and the other inferior, persists. The distinction between sex and 
gender is an important one, and while they are related, their relationship 
is far more complex than the linear correspondence that binary thinking 
implies, where the terms sex and gender are often used interchangeably. 
The idea of sex is most often grounded in the biological/material body, 
while gender has come to represent the profound consequences of the social 
meanings we have given to a binary sex system, i.e. gender represents the 
social rules of masculinity/femininity of inhabiting male/female bodies. 
Even this formulation shows binary thinking, where sex is biological, and 
gender is social, thus invoking yet another binary frame of a biology/social 
binary.1 While human bodies may or may not be strictly binary in their 
phenotypic manifestations,2 the idea of binary sex persists, as do claims 
of a vast apparatus of gender differences. We consistently see claims of 
gender differences in men and women, such as aggression, nurturing, logic, 
rationality, emotions, scientific and mathematical ability. 
Decades of work in the social studies of science remind us that 
scientific claims of difference – be they about sex, gender, race, class, 
caste or sexuality – have been a persistent aspect of science. Claims of 
biological difference most often support the superiority of the political 
elite and the inferiority of those in the margins (Bleier 1984, Hubbard 
1990, Birke 1999, and Fisher 2011). Science, it would seem, is ultimately 
a social institution that reproduces and replicates the power structures that 
it is located in. Science and society co-produce, indeed co-constitute each 
other (Reardon 2001). Scientific knowledge emerges from the circulation 
of knowledge, as knowledge continually travels between science and 
society, and back (Fausto Sterling 1987, 2003). Far from being removed 
from politics, or living up to its claims of value neutrality, science is deeply 
implicated in structures of power – and thus implicated in the histories of 
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sex, gender, race, and caste (Rose 1994). As it has grown to be a powerful 
institution, science has also been embraced and utilised by programmes 
and movements for social justice. Science is increasingly a contested zone, 
and has emerged as a tool for progressive movements and causes, and 
with its increasing democratisation it has also become a tool for liberatory 
movements (Campbell 2009 and Benjamin 2013). However, it should be 
no surprise that a history where women have been seen as inferior beings, 
would produce a science that is male dominated, and developed as a “world 
without women” (Noble 1992 and Schiebinger 1989). In the world with a 
“persistent patriarchy,” scientific knowledge continues to be shaped by the 
interests of the powerful and against science’s more democratic potential 
(Longino 1990 and Sur 2008). This history of science that developed as an 
all-male province has profoundly shaped scientific practices, its cultures and 
knowledge production (Subramaniam 2014). Furthermore, the development 
of science has shaped and been shaped by the politics of race, class, caste 
and sexuality, as well as by colonial expansion. Science and technology have 
been “the jewels in the crown of modernity” (Harding 2012:2), central to 
the expansion of empire and critical to the contemporary world. Sciences 
should, therefore, be understood as “sciences of empire” (Schiebinger 
2004); indeed almost all modern science should be understood as “science 
in a colonial context” (Seth 2009).
While one can explore how science has shaped and been shaped by 
various structures of power such as sex, gender, race, caste, colonialism, 
heterosexuality, ableism, etc., I will focus on sex and gender in this paper. 
Ideologies of sex and gender are not neutral – those qualities that are deemed 
to be masculine have been historically overvalued and overrepresented in 
the hallways of power, compared to those deemed feminine (Schiebinger 
1989, 1993). Social studies of science shows us that these gendered ideas and 
ideologies go deep, permeating most aspects of knowledge, including science 
and scientific knowledge production (Collins 1999). Ideas and ideologies 
of sex and gender permeate our thinking beyond the human body. Early 
feminist work has argued that western science has historically been imbued 
with masculinist ideals - to control nature, develop reductionist models of 
nature, extoll an impossible “objectivity” in our studies of the natural world 
(Harding 1991, 2006, 2012). Scientific temperament extols the objective, 
logical, rational, unemotional, removed from the social and political world. 
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In contrast, we see less attention to ideas deemed feminine, such as less 
exploitative models of living with nature, interdisciplinary models of 
knowledge production and subjective explorations of the world. Feminists 
have long argued that masculinity and femininity together represent an 
important resource for all humans, and have called to dismantle our binary 
system for a set of values that embraces feminist ideals, appreciating the 
strengths of both the masculine and the feminine.
This special issue is dedicated to the topic of “women and biotechnology.” 
Three decades of feminist scholarship have shown this to be a more 
complex topic than initially meets the eye. First, we can of course talk 
about women scientists who participate in biotechnology – we can ask 
about the demographics of women in biotechnology, and whether and in 
what proportion they are represented in different levels of research and 
administration. We can also ask if the presence of women shapes the kind of 
research that is undertaken. Second, we can explore the gendered dimensions 
of biotechnology, beyond the presence or absence of women. How have 
gendered ideas and ideologies shaped the innovations in biotechnology? 
What are the goals of biotechnology and whose interests do they serve? What 
questions have we asked, and what have we not? Finally, we can ask how 
biotechnology has shaped the lives of women at large. Has it empowered 
and improved the lives of women or has it continued to marginalise women 
and their interests? Each of these questions is related to the others. 
According to Kiran Mazumdar Shaw, an Indian entrepreneur, and 
founder of biotech company Biocon Limited, “Today anything can be done 
– we the techniques.” Whereas Vandana Shiva, Scientist and Environmental 
Activist said, “You are not carrying the world on your shoulder. It is good 
to remember that the planet is carrying you.” The two statements show 
that the binary positions permeate our discussions around women/gender 
and biotechnology - is it good or bad? Is it progressive or reactionary? Is 
it good for women or harmful? Is it life affirming or life-killing? Should 
feminists support it or oppose it? Kiran Mazumdar Shaw sees the promises 
of technology, and believes it is a tool for the social progress of India. As a 
pioneer in the field, and as a woman, she sees technology as a site of social 
justice and believes in its promises for women in India (Weidmann 2014). As 
she says, technology can have wide impact and be a boon to India and that we 
should use it, and because with technologies’ wide reach and its innovative 
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potential, “anything can be done.” In contrast, Vandana Shiva, an Indian 
environmental and anti-globalisation activist and author has largely staked 
positions against biotechnology, which she sees as macho and masculinist 
and as a destructive system of people and the planet (Shiva 1988, 2005). 
Instead, she advocates that we return to traditional systems of farming in 
India, that are more woman-focused and that draw on the feminine prakriti 
to return to a more human and natural “nature.” Both figures are beloved 
in their respective communities of pro-technology and anti-technology. 
Rather than stake a pro- or anti-technology position, I ally with the 
emerging consensus in science and technology studies that technology is 
best understood not as always either good or evil, or as a neutral tool that 
is subsequently appropriated by political actors for either good or evil, bur 
rather as a site that is intricately interconnected with power and society. 
We, thus, need to trace and understand how technology becomes a site of 
knowledge and social action and how it is connected to other forces and 
structures in society (Wajcman and MacKenzie 1985 and Takeshita 2011). 
Women, Gender and Science
Representations of scientists are strongly correlated with the demographics 
of power in a nation. Studies have shown that members of socially more 
powerful groups are better represented in more prestigious fields. A history 
of women in the sciences, both historically and in contemporary times, 
shows the continued marginalisation of women and minority groups across 
the globe (Alic 1986, Rossiter 1982, Abir-Am and Outram 1987 and Gupta 
2007). In India, we see the strong effects of the politics of gender and caste 
in shaping science and the practitioners of science in India (Sur 2011). While 
the numbers of women in undergraduate and graduate education have risen, 
representation in the scientific workforce remains low (Huyer and Halfkin 
2013). Furthermore, there are patterns to women’s under-representation 
across the disciplines in the sciences. Like in several other countries, in 
India, women tend to be more highly represented in the life sciences than the 
physical sciences and engineering. Demographic patterns across the globe 
also suggest that women’s representation is correlated with the status of the 
sub-discipline in the country. Disciplines with higher status and economic 
importance show greater male dominance. For example, computer science 
as a field began with a much higher proportion of women, and despite 
Colonial Legacies, Postcolonial Biologies
20     Asian Biotechnology and Development Review
considerable efforts, the proportion of women has dropped as the field has 
become more important and prestigious (Stross 2008). Despite being a 
‘hot’ field, and despite efforts to increase the numbers of women scientists, 
the proportion of women in computer science has declined, leaving it very 
much a “boy’s club” (Banerjee 2014).  Such a pattern is a strong reminder 
that women’s under-representation is tied to socio-economic and political 
factors rather than biological unsuitability (Campion and Shrum 2004, 
Subramanian 2007, Varma 2010). Women and gender are also not universal 
categories, always mediated by the politics, race, religion, caste, class, and 
sexuality (Beoku-Betts 2004 and Sur 2011). While there is scant data on 
the demographics of women scientists in India, the data that is available 
shows a similar pattern to the rest of the world. Women scientists remain 
under-represented across the fields in science and engineering (Gupta and 
Sharma 2002 and Kumar 2009). Women scientists are represented in higher 
numbers in the biological sciences, but women scientists in India still form 
a small proportion of women, and a minor portion of working women in 
India (Bal 2004).
Why the under-representation? Competing theories have postulated 
different reasons: whether women are not interested in science, not 
good at science or whether they leave the sciences because of a hostile 
or unwelcoming environment (Valian 1999, Cech and Blair-Loy 2010 
and Garforth and Kerr 2009). Studies over the last several decades have 
documented that both historically and in the present, women show great 
interest in science and perform well academically (Rosser 2008). Indeed, 
women have persisted in their love of science, often under arduous 
conditions (Rossiter 1982 and Alic 1986). Despite decades of programmes 
to support and nurture women scientists, women have not achieved parity, 
especially at more senior levels. Studies suggest that this is because of 
continued inequities within science, and persistent barriers and systematic 
discrimination of women in science and technology (Bystydzienski and Bird 
2006). To describe the under-representation, a recurring metaphor in the 
field is the “pipeline” and the women in science literature has documented 
a very “leaky pipeline” as women leave the scientific workforce at all 
stages of their travel from elementary school to the top echelons of science 
(Handelsman 2005 and Subramaniam 2009). Efforts to increase women 
in the sciences are often premised on “plugging” the leaks in the pipeline. 
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Others have argued that rather than “fixing” women to inhabit the culture of 
science, we should “fix” science to be a more inclusive institution (Rosser 
2004). After all, increasing the number of women in the sciences does not 
automatically produce a culture that is more progressive or supportive of 
women (Garforth and Kerr 2009). Data suggests that women in sciences are 
participants in the scientific enterprise and thus often driven by the same 
goals and objectives of mainstream science (Acker 2000 and Garforth and 
Kerr 2009).  Scientific culture that developed as a “world without women” 
continues to betray these histories (Traweek 1992). We need to see structural 
change, where the priorities of science, its mechanisms of judging merit, 
its policies for promotion, and advancement, and its methodologies of 
knowledge production need to change to recognise different life histories, 
priorities and needs of a diverse workforce. As a result, recent proposals to 
increase the representation of women in the sciences have shifted from a 
focus of changing “women,” to a focus of making science a more hospitable 
space for all scientists. Ultimately, strategies to “decolonise,” “degender,” 
and “regender” science are necessary to imagine a more progressive and 
democratic science. 
While women remain under-represented in the higher echelons in 
biological sciences, and while the women in the field have not transformed 
biotechnology in significant ways, the impact of the sciences on women 
goes beyond the number of women who are in biotechnological fields. 
The 20th century was labelled the “century of the gene” (Keller 2002), 
and the biological sciences, and biotechnology, in particular, represent the 
site of great investment and focus in contemporary times. The field has 
infiltrated nearly all walks of life – from manipulating DNA to large-scale 
biological warfare, from bio-nano-particles to industrial replicators. What 
has biotechnology delivered, for whom does it work, and what impact has 
it had on the lives of women? 
Biotechnological Body
Biotechnologies involve technologies of biological organisms, but their 
relationships to gender are best explicated by looking at biotechnologies 
of human bodies. Our imaginations around the body and its workings have 
been thoroughly biologised in the 21st century. In a wonderful exploration 
of biotechnology in India, Shiv Viswanathan and Chandrika Parmar (2002) 
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conclude that the biotechnology controversy around genetically modified 
organisms (and I would argue other biotechnology debates) has all the 
makings of a great “moral debate.” The two epigraphs that began this 
essay show us the contours of that great moral debate. Is biotechnology 
a tool we should embrace in our visions of a progressive and democratic 
society? Or is it a technology that ushers in a dystopic future for humanity? 
Viswanathan and Parmar (2002) argue that “biotechnology as a scientific 
venture in the populist and technocratic imagination is alive and well but 
biotechnology as a part of the new democratic imagination committed to the 
rule of law and regulation, and governance sensitive to the ideas of risks, is 
fragile. One needs to build concrete set of institutions around the practice of 
biotechnology and locate it within the wider debates on innovation, property 
and the commons.” They remind us that biotechnology is best understood 
not just as a set of methods that can be deployed to varied means and 
ends, but as an institution that has been developed in the aid of particular 
political and ideological visions (Bliss 2012). The research questions 
asked and the innovations that are developed in biotechnology are tied to 
funding agencies, corporations or governments and their priorities. We can 
certainly imagine technologies that are in the service of women, and even 
feminist technologies of the body. However, biotechnology as a field and 
like much of contemporary science and technology, has often served the 
interests of the powerful. The interests of women, feminist and democratic 
ideals have often been marginalised in the founding and governing visions 
of the field. I use two very different examples, transnational surrogacy 
and genomic medicine to illustrate this point. Transnational surrogacy is 
a burgeoning privatised industry in India that commodifies the body of 
“individual” women, and relies on a local and regional infrastructure to 
foster economic transactions transnationally. In contrast, recent investments 
in an Indian Genome Variation Initiative Consortium (IGV) work at the 
molecular level, are imagined as a national database, and rely on a national 
infrastructure and imagination. India is not alone, as many such projects 
have been undertaken by other countries in Asia. These projects have strong 
backing from the state, creating new linkages between genetic identities and 
national sovereignty. The emerging biotechnology industry in Asia can be 
seen as a rising “bionationalism” that is reshaping the global development 
of genomics, as Asian and other developing countries are asserting their 
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“genomic sovereignty” (Benjamin 2009, Kelly and Nichter 2012 andOng 
and Chen 2013). Exploring these two very different cases, will illustrate how 
contemporary biotechnology is imagined and how in both cases, women 
and gender are impacted unequally in the goals, objectives and imaginations 
of biotechnology.
Bodies of Biotechnology: The Case of Transnational Surrogacy
Transnational gestational surrogacy is a commercial industry that has grown 
into a multi-billion dollar industry in India. Gestational surrogacy involves 
implanting an embryo created through in-vitro fertilisation (IVF) into a 
surrogate mother who carries the foetus to term. The child is then given to 
the commissioning parents. In contrast to genetic surrogacy, a gestational 
surrogate mother according to the law and medical understandings does 
not ostensibly contribute any “genetic” material and is, therefore, unrelated 
to the foetus. The exponential rise in this practice is evidenced by the 
sharp rise in estimates – from US$ 445 million in 2008 to over US$ 20 
billion in 2011 (Nayak 2014:2). The term “surrogate” is derived from the 
Latin subrogare, which means “appointed to act in the place of” (Sama 
2012). While commercial surrogacy is illegal in many parts of the world, 
it is a growing industry in India, largely unregulated since inception and 
only recently beginning to be regulated (Menon 2012). Technoscientific 
surrogacy employs high tech reproductive technologies utilising a low tech 
and economically marginalised workforce (Goodman 2008). 
Over the last decade, India has emerged as a site of “reproductive 
tourism,” where infertile couples from India, the Indian diaspora and non-
Indians abroad have come to India to what has come to be termed as “rent 
a womb” for their potential embryos from a gestational surrogate (Carney 
2010 and Voigt et al. 2013). This is a global industry with complex and 
multiple circuits of travel where intended parents enter into “reproductive 
exile” (Inhorn 2012) to go to another country for conceiving a child. The 
circuits are so complex and transnational that some Indian couples are priced 
out of India, and have to travel to foreign countries like Dubai for various 
forms of reproductive technologies (Inhorn 2012). 
A growing number of academic and journalistic accounts have chronicled 
complex and fascinating narratives of the surrogacy and the experiences of 
surrogates (Pande 2014, and Vora 2015). These narratives on the business 
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of commercial surrogacy are striking, and in examining stories about media 
reports and research accounts of surrogacy, a consistent narrative has 
emerged. The framing of the debates as Susan Markens (2012) argues, have 
revolved around the questions of whether the globalisation of reproductive 
labour is an exploitation of the surrogate mother or an opportunity for her 
and in a related vein whether the surrogacy narratives are best understood as 
one of gendered altruism or one of gendered empowerment – the literature, 
thus, presents this as an ethical issue of reproductive liberalism versus 
exploitation (Banerjee 2010).
First, surrogacy is presented both to the surrogates and the world as 
a de-sexualised model of reproduction – this is a technologised mode of 
reproduction ostensibly without the relational or ethical messiness of sex 
or sexuality. Second, the bodies of women are commodified as a “rent a 
womb” enterprise. Depending on the region, caste, class, skin colour, and 
educational background of the woman, the value of the womb varies (Sama 
2012). Third, the pregnancy is entirely scripted as a medical process rather 
than an affective model of mothers or mothering. Surrogate mothers carry 
the foetus to term through a medically regulated pregnancy. Indeed, various 
towns in India like Anand, called the surrogacy outsourcing capital of the 
world (Nayak 2014), have become famous for their surrogacy centers 
where surrogate mothers live in hostels for the length of their pregnancy, 
closely surveilled and monitored for optimum foetal development (Pande 
2009, 2014 and Voigt et al. 2013). While there is variation across India, a 
dominant narrative of gestational surrogacy has emerged. 
Those arguing for the positive impact of surrogacy, point to the 
opportunity that gestational surrogacy has opened up as a site of labour. 
While there is much criticism about the exploitative and coercive nature 
of gestational surrogacy, it is important to understand and contextualise 
surrogate bio-labour within other forms of labour. While surrogacy is a very 
intimate and physical form of biolabour, other forms of labour have their own 
exploitative regimes. As Sharmila Rudrappa (2015) shows in her excellent 
ethnography, for some women, surrogacy presents a less exploitative model 
of labour than others, like the garment industry. Rudrappa describes the 
long hours, the physically arduous work, the lack of control, the sexual 
harassment, and at times violence that surround women’s experiences of 
labour in the garment industry. Is this really an improvement on surrogacy, 
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she asks? Surrogacy affords food, rest and relaxation (for some) during the 
duration of the pregnancy, and health care to a population that has little 
access to it – even though these benefits end with the birth. Surrogacy also 
gives women access to money (although there is considerable regional 
variation). Making money in nine months that would usually take her four 
to ten years to make is significant for the lives of women, and their role 
and power within the family and community. The technology of surrogacy 
has also revolutionised our conceptions of the family. It has allowed us to 
imagine and expand our notions of kinship and family (Thompson 2002). It 
has considerably expanded who can have babies and allowed the formations 
of new and more extended transnational family networks. For the affluent, 
surrogacy has opened up new options to deal with the stigma of infertility. 
Given that children and families remain the social net for old age in India, 
technologies of surrogacy have opened up new modes to build families that 
ensure individuals’ future financial and bodily health.
However, critics of surrogacy have also raised important issues. 
Surrogacy has been presented into a medicalised and desexualised model, 
converting traditional ideas of pregnancy to be re-imagined as medicalised 
labour and clinical labour (Cooper and Waldby 2014). In this model, the 
woman’s body becomes a receptacle of commerce (Sama 2012). The 
process of medicalisation is entirely regimented with clear steps and 
protocols that need to be faithfully followed. A prescribed meal, which is 
ostensibly based on western ideas of balanced nutrition, is consumed along 
with regimes of exercise, rest, and relaxation. The language of medicine 
frames so-called medical protocols into the legal contract of gestational 
surrogacy. Thus sexual abstinence, battery of tests and heavy medication 
(rarely explained to the surrogates), c-sections, lack of breast feeding, and 
regimented protocols of hygiene, nutrition and exercise are codified into 
the legal contract ostensibly based on the health of the foetus. Payment for 
the surrogacy (a large portion of which is only available after delivery) is 
dependent on following the medical protocols. The boundaries between 
private and contractual are very blurry leaving very little that remains in 
the private sphere of surrogate mothers, and thus giving them little control 
and agency in the process (Pande 2009, and Sama 2012).
Campbell (1992) argues that “contemporary medicine has transformed 
the human body into a source of instrumental value, a resource of value 
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to others: patients, physicians, and researchers…Such practices seem to 
presuppose a basic feature of property, that is, the capacity and power of 
alienation or transfer.” Indeed, gestational surrogacy disaggregates women’s 
bodies as resources rendering the womb as a disembodied, “empty” and “not 
being used” resource that is available to make money. Like sperm, ova, and 
organs, wombs have also been isolated as an individual commodity (Cohen 
2009 and Nayak 2014). The body is entirely abstracted and commodified and 
transformed into a “manufacturing mode” of (re)production (Darling 2014). 
No doubt that we can imagine the technology of surrogacy in an 
equitable, non-coercive or altruistic model. However, the inequalities in 
the world transform such a vision into one riddled with inequities and 
exploitation. Today, techno-scientific surrogacy has reframed the role of 
women in reproduction, one that renders pregnancy and the postcolonial 
female body invisible. In desexualising, medicalising and commodifying 
reproduction in gestational surrogacy, the language of mothers and mothering 
is discarded for a new language of bio-labour, commodified organs, and 
disposable bodies. The affective politics of love, of mothers and motherhood 
is only available to the commissioning parents and their future families. 
Thus, techno-scientific surrogacy allows the erasure of some women as 
women and mothers, while enabling the womanhood and motherhood of 
others. This is particular ironic given that infertility rates among the poor 
and marginalised are often higher than richer communities (Roberts 1997). 
Like other innovations around reproduction, such “stratified reproduction” 
organised around hierarchies of race, gender class, ultimately replicate 
and reinforce underlying inequalities rather than erase them (Colen 1995). 
In the practices of contemporary surrogacy, surrogate mothers have little 
bargaining power in the process. This is precisely what some feminists have 
been pushing for – not an end to surrogacy, but in developing regulation that 
protect the rights of surrogate mothers (Sama 2012). Biotechnology and its 
imaginations it would seem replicate the interests of power within the larger 
political economy. It enables the desires of the elite through the bodies of 
the poor. Whether it is good for women or not, depends on which women 
we care about, whose interests are the basis of the laws and regulations 
that govern surrogacy. An attention to the power and inequities that shape 
the system of surrogacy can allow us to imagine the more progressive 
possibilities of bio-technology. Realising them is possible only when the 
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nexus between power, gender and technology is understood and forms the 
basis for regulation of technology.
The Biotechnology of Bodies: The Indian Genome Variation Project
From women’s bodies and their pregnancies, let us move to the molecular 
level. Over the last few decades, we have seen the “molecularisation” of life 
(Rabinow and Rose 2006, Rose 2006, and Egorova 2013). The biology of 
organisms, rather than being considered in their entirety, and in the context 
of their environments, are increasingly reduced to their molecular selves. 
The Human Genome Project, the HapMap Project, the Genographic projects 
are all projects about the molecularisation of life. India has embarked on 
its own indigenous genomic database. As critics have pointed out, the 
molecularisation of life has shifted our conceptions of ill health and disease 
from a focus on the social contexts of poverty and access to nutrition and 
care, to a presence of a genetic propensity to ill health or disease (Kahn 2009, 
Dumit 2012, and Chambers et al. 2014). Like transnational surrogacy, we 
can imagine the progressive possibilities of molecular biology – enabling 
drug production, histo-compatible tissue, interventions in the genetics of 
some modes of cancer, the possibilities of stem cells and other forms of 
regenerative medicine. However, ignoring the social contexts of disease and 
illness (as we have seen in the recent pandemic of Ebola) can be severely 
limiting to global health and welfare.
In keeping with global trends in biotechnology, India has launched its 
own biotechnology revolution. The Indian Genome Variation Initiative 
was initiated in 2003 involving six constituent laboratories of the Council 
for Scientific and Industrial Research (CSIR), and with funding from the 
Indian government. They include:  Institute of Genomics and Integrative 
Biology (IGIB), Delhi; Centre for Cellular and Molecular Biology (CCMB), 
Hyderabad,; Indian Institute of Chemical Biology (IICB), Kolkata; Central 
Drug Research Institute (CDRI), Lucknow; Industrial Toxicological 
Research Centre (ITRC), Lucknow; and the Institute of Microbial 
technology (IMTECH), Chandigarh.
This is an ambitious project, conceived as the “first large-scale 
comprehensive study of the structure of the Indian population” (Narang 
et al. 2010) with wide-reaching implications. As the project organisers 
argue, India is a large, populous and diverse country on many levels. It 
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comprises “more than a billion people, consists of 4693 communities with 
several thousands of endogamous groups, 325 functioning languages and 
25 scripts.” The project argues that to “address the questions related to 
ethnic diversity, migrations, founder populations, predisposition to complex 
disorders or pharmacogenomics, one needs to understand the diversity and 
relatedness at the genetic level in such a diverse population” (Indian Genome 
Variation Consortium 2005). The project has been touted as one of disease 
gene exploration (Indian Genome Variation Consortium 2008). They have 
identified over a thousand genes to study. These genes have been “selected 
on the basis of their relevance as functional and positional candidates in 
many common diseases including genes relevant to pharmacogenomics.” 
(Indian Genome Variation Consortium 2005).
The Indian project joins a global shift in turning human health into a 
biotechnological project, with a specific end goal, a pharmaceutical solution, 
ushering in the “pharmceuticalisation” of life. International genomic 
efforts, such as the HapMap projects are interested in the global distribution 
of genomic variation. To be sure, the development of biotechnology – 
infrastructure, methods, instruments, scientists, methods, data – can be 
important and revealing. With the onset of such investments India has arrived 
as an international player and an emerging power in biopolitical governance. 
In particular with the geneticisation of biomedicine, such projects attempt 
to ascertain both the global distribution of genetic diseases, as well as the 
distribution of disease susceptibilities, arguing that such distributions will 
powerfully shape future health care globally. These aspirations are very 
much linked to the pharmaceuticalisation of medicine (Pollock 2014), and 
the development of pharmacogenomics whereby genetic susceptibilities 
spawn new classes of drugs. Countries such as India and Mexico are seen 
as “Pharma’s Promised Lands”  (Benjamin 2009). 
While one can no doubt argue that it is important for a nation like India 
to assert their bio-political independence, nurture local talent and build a 
strong infrastructure, and pursuing a purely genomic solution to health 
is also severely limiting and short sighted. We must ask why millions of 
dollars of public funding is invested into sequencing the Indian genome. 
Why would a country still reeling from extreme poverty, where preventable 
and communicable diseases consume most of its citizen deaths invest so 
much in DNA technology? India’s health statistics still looks so abysmal 
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even after decades of strong economic growth; less than one per cent of 
its GDP is spent on public health care and has only nine hospital beds per 
10,000 people, compared to an equivalent rate of 41 per 10,000 in China 
(New York Times, Editorial, 2014). 
The “Indian Genome Project” argues that DNA technology will aid 
the health and wellbeing of its citizens through sequencing genomes and 
uncovering disease vulnerabilities. In one of their publications they suggest 
that the genetic landscapes of India provide us with “a canvas for disease gene 
exploration.” Yet the vast majority of deaths in India are due to causes that 
are well recognised, and preventable with current technology. Transforming 
ill-health into a genetic problem with a pharmaceutical solution supports a 
particular ideological and economic agenda. If ill-health is a problem due 
to individual’s genetic propensity to be ill rather than the inequities of an 
every day life of poverty, polluted environments, and the lack of access to 
good health care, then the problem and the solutions shift from the state 
and public policy to the individuals and their faults. Similarly, a solution 
that is about pharmaceutical drugs rather than access to good air, water, and 
nutrition similarly benefits certain economic players; the solutions support 
the development of (most often) a privatised drug industry rather than 
public infrastructure that is accessible for all. Strong political, economic, 
and ideological assumptions undergird these biotechnological assumptions 
and priorities. In the United States, we have seen similar moves as the 
category of “race,” once argued to be a social and not biological category, 
has been re-biologised in recent times (Stepan 1982, Gannett 2001, Kahn 
2005, Reardon 2005, and Hammonds and Herzig 2009). 
Surely, improved health in India can be imagined to be both social and 
technological? Studies on the ill health of the Indian population point to 
the need for important social and political interventions. 
In a country where women feed themselves last, the health statistics of 
women are particularly horrendous. More than 90 per cent of adolescent 
girls in India are anaemic, and 40 per cent of Indian mothers are underweight 
(Harris 2015). Global public health presents the poor in India as one of the 
most abject populations in the world. Despite evidence that genetics play 
little role in much of this ill health (Harris 2015), the funding of a mega 
genomic project rather than one of public health infrastructure is striking.
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In response to the ill health within India, we need to include the proven 
strategies and knowledge that science and technology has already produced. 
India needs more investment in meeting basic health and nutritional needs, 
and should address the disparities and inequities in health. A pharmacogenetic 
solution cannot be our only option. These shifts in biomedicine have lead to 
what Donna Dickenson calls ‘Me Medicine,’ a set of practices that aims to 
focus on an individual’s needs and interests have resulted in mixed results. 
Her analysis shows that the scientific plausibility is not the key determining 
factor in availability of new treatments and options such as umbilical cord 
banks. Rather what has driven recent biomedicine is the development of 
new markets, products and services catering to individual needs, perceived 
threats and risks drive the diffusion and availability of products and services. 
Instead, she calls for a return to a ‘We Medicine’ approach that emphasises 
investment in public health infrastructure that has already extended our life 
spans radically. ‘We Medicine,’ that emphasises technology used for the 
common good coupled with better regulation of biotechnology industry, 
she argues should be our path forward to restoring the idea of the commons 
in modern biotechnology. It is important to critically examine what goes 
in the name of common good from gender perspective and who matters in 
the ‘We Medicine’ (Dickenson 2013).
The Possibilities of Postcolonial Biologies
What both case studies show, I hope, is the failure to consider women in our 
biotechnological imaginations. Biotechnology gets heralded as the economic 
engine of a nation, even while its imaginations continue to marginalise a 
large proportion of the population. What is often missing in the discussions is 
a contextual understanding of biotechnology, locating it within its economic, 
political, cultural, and national contexts. It is not that biotechnology cannot 
be used towards more liberatory goals, but rather that the dominant face of 
biotechnology are ones that moved us to more corporatised, commodified, 
and privatised ventures. By locating biotechnology within these larger 
forces, we can see the broad and myriad issues that shape the relationship 
of women and biotechnology. 
How should we study the world? A specialised academia has vivisected 
an inextricably interconnected world into myopic disciplines that have 
divided the world into binary categories of nature/culture, and human/non-
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human.  One of the central methodological insights of the feminist studies 
of science and technology has been refuting the binary worlds of nature 
and culture. Defining the object of the biological sciences as non-human 
life creates the illusion of a human-free world, a world removed from 
ideology, politics, and culture. Conversely, human culture remains in the 
purview of the social sciences and humanities, a world removed from the 
natural. But what if we refuse this nature/culture binary? In coining the term 
naturecultures, Donna Haraway challenges us to reject the binaries of nature 
and culture and attend to the constant traffic of discourses, information, 
and theories between the worlds of natures and cultures (Haraway 1999). 
There is no nature or culture, only naturecultures. Similarly, many feminists 
who are critical of the impact of the sciences and technology on women’s 
lives have refused to support an anti- science/technology/ globalisation, 
arguing instead that we need to reimagine science and technology and their 
relationship with society (Haraway 1997). In this paper, I have explored 
two very different case studies of biotechnology in India to show how our 
politics of gender - shapes and is shaped by biotechnology and through 
it, the lives of women. I use these two very different case studies because 
they work across different scales and levels, demonstrating how gender 
gets deployed in very similar ways across macro- and micro-scales of 
analysis. In each, we see how objective sciences and the knowledge they 
produce are deeply entangled in the politics of gender in a post-colonial 
nation. Post-colonial biologies thus get shaped by the gendered scripts of the 
colonial legacies that it inherited (Verrran 2002), and subsequently by the 
complex political shifts in independent India. Ultimately, biotechnology is 
an exciting site of innovation, and has the potential to enable democratic and 
progressive visions of society, but in practice has instead gotten imbricated 
in the old colonial and gendered scripts of the nation. But contestations 
over technology open up new spaces for innovation and the possibilities 
for developing a biotechnology as if women really mattered. 
Endnotes
1 This is a very simple rendition of the history of sex and gender. Both terms are today 
seen as much more complex. See Fausto Sterling (2012).
2 Considerable work on intersex has shown that human bodies appear as a sexual 
continuum rather than in only two categories of male and female. See Dreger (1998).
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